Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci

International Journal of Antimicrobial Agents

Volumn 19, Issue 4, 2002, Pages 299-311

  Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic; Infection; Sterically stabilized liposomes; Targeting

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFTAZIDIME; CIPROFLOXACIN; DRUG CARRIER; GENTAMICIN; IMMUNOLIPOSOME; LIPOSOME; STREPTOMYCIN;

ANTIFUNGAL ACTIVITY; BACTERICIDAL ACTIVITY; CAPILLARY PERMEABILITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; ENCAPSULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION; LEUKOCYTE; LIPID COMPOSITION; LUNG ASPERGILLOSIS; MACROPHAGE; NONHUMAN; PHAGOCYTE; PNEUMONIA; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; INFECTION; LIPOPROTEINS; LIPOSOMES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 0036222748     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00021-3     Document Type: Conference Paper

References (110)

1. The past, present, and future uses of liposomes in treating infectious diseases
2. Liposomes opportunities in drug delivery
3. Liposomal drug formulations. Rationale for development and what we can expect for the future
4. Liposomes in the treatment of parasitic, viral, fungal and bacterial infections
5. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications
6. Liposome deposition in vivo III. Dose and vesicle-size effects
7. Liposomes in the treatment of infections
8. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model
9. Delivery of antimicrobials to infected tissue macrophages
10. Biopharmaceutical aspects of lipid formulations of amphotericin B
11. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B
12. Lipid-based amphotericin B formulations: from animals to man
13. Lipid formulations of amphotericin B
14. New development in the diagnosis and management of invasive fungal infections
15. Lipid-based antifungal agents: current status
16. Lipid-based amphotericin B: a review of the last 10 years of use
17. Trends and developments in liposome drug delivery systems
18. US Food and Drug Administration approval of AmBisome® (liposomal amphotericin B) for treatment of visceral leishmanisasis
19. Long-circulating liposome therapeutics: from concept to clinical reality
20. Mechanism of Stealth® liposome accumulation in some pathological tissues
21. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study
22. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles
23. Fate and behavior of liposomes in vivo: a review of controlling factors
24. Long-circulating liposomes containing antibacterial and antifungal agents
25. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®)
26. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis
27. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposoms after a single or repeated intravenous administration in the Rhesus monkey
28. Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration
29. Comparative efficacies of liposomal amikacin (MiKasome®) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses
30. UTI treatment using liposomal amikacin (MiKasome®) (abstract P194). 9th European Congress of Clinical Microbiology and Infectious Diseases (Berlin)
31. Safety, tolerance and pharmacokinetics of AmBisome® in neutropenic patients
32. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
33. Liposomal amphotericin B (AmBisome®) for fungal infections in immunocompromised adults and children
34. Large unilamellar liposomes with low uptake into the reticuloendothelial system
35. Targeting of liposomes to tumor cells in vivo
36. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues
37. The role of surface charge and hydrophilic groups on liposome clearance in vivo
38. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
39. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles
40. Liposomes for the sustained drug release in vivo
41. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes
42. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
43. Liposomes containing synthetic lipid derivatives of poly(ethyleneglycol) show prolonged circulation half-lives in vivo
44. Sterically stabilized liposomes
45. How do polymers prolong circulation time of liposomes
46. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
47. Controlling liposome blood clearance by surface-grafted polymers
48. Pharmacokinetics of stealth versus conventional liposomes: effect of dose
49. Biological properties of sterically stabilized liposomes
50. Antibacterial activity of liposome-entrapped ampicillin in vitro and in vivo in relation to the lipid composition
51. Versatility in lipid composition showing prolonged circulation with sterically stabilized liposomes
52. Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum
53. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defence and low bacterial susceptibility to gentamicin
54. Pharmacokinetics of long circulating liposomes
55. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
56. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue
57. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes
58. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics
59. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating
60. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue
61. Thermodynamic analysis of the permeability of biological membranes to non-electrolytes
62. Liposomes for scintigraphic detection of infection and inflammation
63. Radiolabelled liposomes for scintigraphic imaging
64. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue
65. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes
66. Targeting of antibiotics in bacterial infections using pegylated long-circulating liposomes
67. In vivo synergistic interaction of liposome-encapsulated gentamicin and ceftazidime
68. Improved efficacy of ciprofloxacin administered in polyethyeneglycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats
69. Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection
70. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′, 3′-dideoxyinosine
71. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells
72. Pharmacokinetics and tissue distribution of long circulating liposomal formulation of 2′, 3′-dideoxyinosine
73. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease
74. Anti-HIV activity of amphotericin B-cholesteryl sulfate colloidal dispersion in vitro
75. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1
76. Treatment with liposome-bound recombinant tumor necrosis factor-α suppresses parasitemia and protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice
77. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin
78. Biodistribution of liposomal amphotericin B (AmBisome®) versus amphotericin B-desoxycholate (Fungizone®) in immunocompetent uninfected mice as well as in leukopenic mice infected with Candida albicans
79. Sterically stabilized amphotericin B liposomes: toxicity and biodistribution in mice
80. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice
81. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice
82. Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome® and Fungizone® against intracellular Candida albicans in murine peritoneal macrophages
83. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats
84. Liposomal amphotericin B (AmBisome®) reduces dissemination of infection as compared to amphotericin B-desoxycholate (Fungizone®) in a newly developed animal model of one-sided pulmonary aspergillosis
85. Enhanced encapsulation of amphotericin B into liposomes by complex formation with polyethylene glycol derivatives
86. Molecular localization and state of amphotericin B in PEG liposomes
87. Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases
88. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice
89. Spectroscopic investigation of the molecular state of nystatin encapsulated in liposomes
90. The uptake mechanisms of inflammation- and infection localizing agents
91. Sterically stabilized liposomes labelled with Indium-111 to image focal infection
92. Detecting infection and inflammation with technetium-99m-labelled staelth® liposomes
93. Optimization of technetium-99m-labelled PEG liposomes to image focal infection: effects of particle size and circulation time
94. Scintigraphic imaging of bacterial and fungal infection in granulocytopenic rats
95. Dual radiolabelled liposomes: biodistribution studies and localization of focal sites of infection in rats
96. Labelled stealth® liposomes in experimental infection: an alternative to leukocyte scintigraphy?
97. Technetium-99m labelled liposomes to image experimental arthritis
98. Scintigraphic evaluation of experimental colitis in rabbits
99. Technetium-99m-labelled liposomes to image experimental colitis in rabbits: comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC IgG
100. 99mTc-HYNIC IgG
101. Imaging experimental osteomyelitis using radiolabelled liposomes
102. Scintigraphic evaluation of experimental chronic osteomyelitis
103. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies
104. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma: the International SL-DOX Study Group
105. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
106. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation